{"id":453582,"date":"2021-03-09T08:03:28","date_gmt":"2021-03-09T13:03:28","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=453582"},"modified":"2021-03-09T08:03:28","modified_gmt":"2021-03-09T13:03:28","slug":"cue-biopharma-to-host-business-update-call-and-webcast-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast-2\/","title":{"rendered":"Cue Biopharma\u00a0to Host Business Update Call and Webcast"},"content":{"rendered":"<div class=\"mw_release\">\n<p>CAMBRIDGE, Mass., March  09, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VkcCXIp_EmdicdwvQkY6Qf-w4SNHUkwz1UssfX51aZh37haYKBA5xsuBNwG6AK19A0VYsAEJLAvjeBNs91P8MW6JXA5-5gqOxt9egf5UkJc=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Cue Biopharma, Inc.<\/a> (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient\u2019s body, announced today it will host a conference call and webcast to provide a business update on\u00a0Tuesday, March 16, 2021\u00a0at\u00a04:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company\u2019s\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WtqWhxemsM_d_VPM-IDyBl6TGrhavqlPYqdVo6ZukbCiUFvyyDNFwwROxNM6lSrEBxpIeWcUEPh3Cgn7Yo3WZF1mxS3IHGCq45IxK3I2Z-qPx4k3z4jkotaEsuk6cr5B\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">website<\/a>.<\/p>\n<p>Members of the\u00a0Cue Biopharma\u00a0executive management team will provide clinical updates on the Company\u2019s ongoing CUE-101 Phase 1 dose escalation monotherapy trial, which will include new patient data, and on the combination trial KEYNOTE-A78, where CUE-101 will be evaluated in combination with KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab) as first-line treatment for HPV+ recurrent\/metastatic head and neck squamous cell carcinoma. Management will also provide an update on the Company\u2019s most recent technology platform developments and pipeline progress as well as updates on its strategic objectives and anticipated milestones.<\/p>\n<p>\n        <strong>Tuesday, March 16 at\u00a04:30 p.m. EDT<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:50%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:26%;width:26%;min-width:26%\">\n            <strong>Investors:<\/strong>\n          <\/td>\n<td style=\"max-width:74%;width:74%;min-width:74%\">877-407-9208<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>International:<\/strong>\n          <\/td>\n<td>201-493-6784<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Conference ID:<\/strong>\n          <\/td>\n<td>13716744<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Webcast:<\/strong>\n          <\/td>\n<td>\n            <a href=\"http:\/\/public.viavid.com\/index.php?id=143645\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">http:\/\/public.viavid.com\/index.php?id=143645<\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong>About\u00a0Cue Biopharma<\/strong><br \/>\n        <br \/>Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient\u2019s body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company\u2019s proprietary platform, Immuno-STAT\u2122 <em>(Selective Targeting and Alteration of T cells)<\/em> is designed to harness the body\u2019s intrinsic immune system without the need for ex vivo manipulation.<\/p>\n<p>Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.<\/p>\n<p>For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Alcr1BCSv_I3l_o4AbxV0ol-3-DZzeQOJuwqC-61Wnu0nv3b3T2VdU_yLiX4Zf4nzodFQ3tXw9FsE7Ibyky2KT5FsMCXBCuWZ-sVGLzcick=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.cuebiopharma.com<\/a> and follow us on Twitter <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IpxJckOpBlT6BgJ_rgoJ63vozO8uxlUVGObRMAeXiEv9K85gkk1RUACFgv54eKolApGN6keL01iw0WLNRC4_7waZHwaGXZmaFl5U5Vk6-k4yEZk387fjR1aEYO_zEyYw\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/twitter.com\/CueBiopharma<\/a>.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>George B. Zavoico, Ph.D.<br \/>VP, Investor Relations &amp; Corporate Development <br \/>Cue Biopharma, Inc. <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AG2vnlrgA8BTTa25t8SlJO5SeF8NoGykxBZe7ZThKFHy0hXLJwPtBP9QBaKSDFd9dB5otBYuaSgzx_OnENRf60Sb4dPS9GjsAx2NsvZKLa4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">gzavoico@cuebio.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Darren Opland, Ph.D.<br \/>LifeSci Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Fmg8QrN24RcGvCHxyf9wIjI3mX2V0HqZhAf5IRIHqoYqeDhesLeK3Gqp7rHlRcHhhcWOxWhG81ByQrPCA9Jm6-MnOMPdgzz9rDTumXGvEgg=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">darren@lifescicomms.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjUyMyM0MDU0MzA3IzIwOTI2OTI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/1155c380-4a79-4cae-bc26-db50b2f5711a\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) &#8212; Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient\u2019s body, announced today it will host a conference call and webcast to provide a business update on\u00a0Tuesday, March 16, 2021\u00a0at\u00a04:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company\u2019s\u00a0website. Members of the\u00a0Cue Biopharma\u00a0executive management team will provide clinical updates on the Company\u2019s ongoing CUE-101 Phase 1 dose escalation monotherapy trial, which will include new patient data, and on the combination trial KEYNOTE-A78, where CUE-101 will be evaluated in combination with KEYTRUDA\u00ae (pembrolizumab) as first-line treatment for HPV+ &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cue Biopharma\u00a0to Host Business Update Call and Webcast&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-453582","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cue Biopharma\u00a0to Host Business Update Call and Webcast - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cue Biopharma\u00a0to Host Business Update Call and Webcast - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) &#8212; Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient\u2019s body, announced today it will host a conference call and webcast to provide a business update on\u00a0Tuesday, March 16, 2021\u00a0at\u00a04:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company\u2019s\u00a0website. Members of the\u00a0Cue Biopharma\u00a0executive management team will provide clinical updates on the Company\u2019s ongoing CUE-101 Phase 1 dose escalation monotherapy trial, which will include new patient data, and on the combination trial KEYNOTE-A78, where CUE-101 will be evaluated in combination with KEYTRUDA\u00ae (pembrolizumab) as first-line treatment for HPV+ &hellip; Continue reading &quot;Cue Biopharma\u00a0to Host Business Update Call and Webcast&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-09T13:03:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjUyMyM0MDU0MzA3IzIwOTI2OTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cue Biopharma\u00a0to Host Business Update Call and Webcast\",\"datePublished\":\"2021-03-09T13:03:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast-2\\\/\"},\"wordCount\":342,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjUyMyM0MDU0MzA3IzIwOTI2OTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast-2\\\/\",\"name\":\"Cue Biopharma\u00a0to Host Business Update Call and Webcast - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjUyMyM0MDU0MzA3IzIwOTI2OTI=\",\"datePublished\":\"2021-03-09T13:03:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjUyMyM0MDU0MzA3IzIwOTI2OTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjUyMyM0MDU0MzA3IzIwOTI2OTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-host-business-update-call-and-webcast-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cue Biopharma\u00a0to Host Business Update Call and Webcast\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cue Biopharma\u00a0to Host Business Update Call and Webcast - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast-2\/","og_locale":"en_US","og_type":"article","og_title":"Cue Biopharma\u00a0to Host Business Update Call and Webcast - Market Newsdesk","og_description":"CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) &#8212; Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient\u2019s body, announced today it will host a conference call and webcast to provide a business update on\u00a0Tuesday, March 16, 2021\u00a0at\u00a04:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company\u2019s\u00a0website. Members of the\u00a0Cue Biopharma\u00a0executive management team will provide clinical updates on the Company\u2019s ongoing CUE-101 Phase 1 dose escalation monotherapy trial, which will include new patient data, and on the combination trial KEYNOTE-A78, where CUE-101 will be evaluated in combination with KEYTRUDA\u00ae (pembrolizumab) as first-line treatment for HPV+ &hellip; Continue reading \"Cue Biopharma\u00a0to Host Business Update Call and Webcast\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast-2\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-09T13:03:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjUyMyM0MDU0MzA3IzIwOTI2OTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cue Biopharma\u00a0to Host Business Update Call and Webcast","datePublished":"2021-03-09T13:03:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast-2\/"},"wordCount":342,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjUyMyM0MDU0MzA3IzIwOTI2OTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast-2\/","name":"Cue Biopharma\u00a0to Host Business Update Call and Webcast - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjUyMyM0MDU0MzA3IzIwOTI2OTI=","datePublished":"2021-03-09T13:03:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjUyMyM0MDU0MzA3IzIwOTI2OTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjUyMyM0MDU0MzA3IzIwOTI2OTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-host-business-update-call-and-webcast-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cue Biopharma\u00a0to Host Business Update Call and Webcast"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/453582","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=453582"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/453582\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=453582"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=453582"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=453582"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}